Status:
COMPLETED
Beta-Blocker Evaluation in Survival Trial (BEST)
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Cardiovascular Diseases
Heart Diseases
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
Detailed Description
BACKGROUND: Controlled and uncontrolled studies suggested that beta-blockade improves ventricular function in congestive heart failure. Several trials suggested that beta-blockers may also reduce mor...
Eligibility Criteria
Men and women, ages 18 and over. Patients had compensated congestive heart failure due to idiopathic dilated cardiomyopathy or coronary disease with ejection fraction less than or equal to 0.35, were in the New York Heart Association functional class III or IV, and were taking an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic. Patients with a specific indication for, or contraindication to, beta-blockade were excluded.
Key Trial Info
Start Date :
June 1 1994
Trial Type :
INTERVENTIONAL
End Date :
September 1 1999
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000560
Start Date
June 1 1994
End Date
September 1 1999
Last Update
April 14 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.